RevM10-transduced hematopoietic stem cells

RevM10-transduced hematopoietic stem cells are autologous hematopoietic stem and progenitor cells genetically modified ex vivo with a retroviral vector to express RevM10, a dominant-negative mutant of the HIV-1 Rev regulatory protein that blocks nuclear export of unspliced and singly spliced viral RNAs and thereby inhibits production of infectious virions.[1][5][7] These gene-modified stem cells are reinfused in HIV-1–infected patients with AIDS-related disease (including lymphoma) to reconstitute a progeny pool of CD4+ T cells and other lineages that are intrinsically resistant to HIV-1 replication, with the goal of achieving durable viral control and immune reconstitution as a functional cure strategy.[1][2][5] Early Phase I/II trials by Systemix and collaborators used RevM10-transduced CD34+ hematopoietic stem/progenitor cells (sometimes combined with an antisense HIV-1 pol construct) without or with myeloablative chemotherapy and peripheral blood stem cell transplantation, demonstrating feasibility and safety but only low-level, transient gene marking in vivo and thus limited clinical impact on viral load.[1][2][5][6]

Other names

RevM10 transduced hematopoietic stem cellsRevM-10 transduced hematopoietic stem cellsRevM 10 transduced hematopoietic stem cellsRevM10-treated stem cellsRevM-10-treated stem cellsRevM 10-treated stem cellsRevM10-expressing hematopoietic stem cellsRevM-10-expressing hematopoietic stem cellsRevM 10-expressing hematopoietic stem cellsRevM10 gene-modified hematopoietic stem cellsRevM-10 gene-modified hematopoietic stem cellsRevM 10 gene-modified hematopoietic stem cells